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Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese adults, we now evaluate
safety/tolerability (primary outcome) and long-term efficacy for sustaining weight loss (secondary outcome) over 2 years.
Design: A randomized, double-blind, placebo-controlled 20-week study with 2-year extension (sponsor unblinded at 20 weeks,
participants/investigators at 1 year) in 19 European clinical research centers.
Subjects: A total of 564 adults (n¼90–98 per group; body mass index 30–40kgm
 2) enrolled, 398 entered the extension and
268 completed the 2-year trial. Participants received diet (500kcaldeficit per day) and exercise counseling during 2-week run-in,
before being randomly assigned (with a telephone or web-based system) to once-daily subcutaneous liraglutide (1.2, 1.8, 2.4 or
3.0mg, n¼90–95), placebo (n¼98) or open-label orlistat (120mg 3, n¼95). After 1 year, liraglutide/placebo recipients
switched to liraglutide 2.4mg, then 3.0mg (based on 20-week and 1-year results, respectively). The trial ran from January
2007–April 2009 and is registered with Clinicaltrials.gov, number NCT00480909.
Results: From randomization to year 1, liraglutide 3.0mg recipients lost 5.8kg (95% confidence interval 3.7–8.0) more weight
than those on placebo and 3.8kg (1.6–6.0) more than those on orlistat (Pp0.0001; intention-to-treat, last-observation-carried-
forward). At year 2, participants on liraglutide 2.4/3.0mg for the full 2 years (pooled group, n¼184) lost 3.0kg (1.3–4.7) more
weight than those on orlistat (n¼95; Po0.001). Completers on liraglutide 2.4/3.0mg (n¼92) maintained a 2-year weight loss
of 7.8kg from screening. With liraglutide 3.0mg, 20-week body fat decreased by 15.4% and lean tissue by 2.0%. The most
frequent drug-related side effects were mild to moderate, transient nausea and vomiting. With liraglutide 2.4/3.0mg, the 2-year
prevalence of prediabetes and metabolic syndrome decreased by 52 and 59%, with improvements in blood pressure and lipids.
Conclusion: Liraglutide is well tolerated, sustains weight loss over 2 years and improves cardiovascular risk factors.
International Journal of Obesity (2012) 36, 843–854; doi:10.1038/ijo.2011.158; published online 16 August 2011
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Introduction
Obesity increases risk of developing type 2 diabetes mellitus
1
and cardiovascular disease, the leading cause of death.
2
Reduction of 5–10% body weight improves obesity-related
cardiovascular and metabolic abnormalities,
3–5 but achieving
Received 4 April 2011; revised 5 July 2011; accepted 5 July 2011; published
online 16 August 2011
Correspondence: Professor A Astrup, Department of Human Nutrition, Faculty
of Life Sciences, University of Copenhagen, Rolighedsvej 30, DK-1958,
Frederiksberg C, Denmark.
E-mail: ast@life.ku.dk
13Listed in the Appendix.
International Journal of Obesity (2012) 36, 843–854
& 2012 Macmillan Publishers Limited All rights reserved 0307-0565/12
www.nature.com/ijothis target through diet and exercise is challenging.
6–8
Pharmacological treatment is recommended in addition to
diet and exercise when lifestyle intervention fails.
4,7–9
Liraglutide, an analog of the incretin hormone glucagon-
like peptide-1 (GLP-1), is currently licensed for treatment of
type 2 diabetes at doses up to 1.8mg, after demonstrating
improvements in glycemic control and weight loss in more
than 4000 individuals of the Liraglutide Effect and Action in
Diabetes (LEAD) program, with satisfactory tolerability.
10,11
In obese non-diabetic adults, liraglutide at doses up to 3.0mg
was more effective than orlistat, or diet and exercise alone,
at reducing weight (primary outcome) over 20 weeks.
12
Liraglutide also improved obesity-related risk factors, redu-
cing waist circumference, blood pressure (BP) and the
prevalence of prediabetes.
We now report 2-year results from the extension of the
20-week trial,
12 as well as data after 1 year, the required
duration for demonstrating weight loss/maintenance in
confirmatory phase 3 trials.
7 The primary outcome at 1 year
was weight loss. In the extension at 2 years, we aimed to
evaluate the long-term safety/tolerability of liraglutide
(primary outcome) and efficacy for sustaining weight loss
(secondary) of liraglutide, with dietary therapy and exercise,
and also to examine the effects on cardiovascular risk factors.
Materials and methods
Participants
We performed a randomized, double-blind, placebo-
controlled 20-week trial (RCT) with a 2-year extension. The
data from the 20-week RCT has already been published.
12 We
recruited men and women aged 18–65 years, of stable
weight, with body mass index 30–40kgm
 2 and fasting
plasma glucose (FPG) o7mmoll
 1 (126mgdl
 1) at run-in,
from 19 research sites in 8 European countries. Participants
were recruited by local advertisement or were existing
patients at an obesity clinic or research center. Key exclusion
criteria were type 1 or 2 diabetes mellitus, drug-induced
obesity, use of weight-lowering pharmacotherapy or partici-
pation in a weight-control study within the preceding 3
months, surgical obesity treatment and major medical
conditions. There was no exclusion criterion based on
psychiatric illness. Participants gave written informed con-
sent. The protocol was approved by local ethics committees
and the trial performed according to the Declaration of
Helsinki
13 and Good Clinical Practice Guidelines.
Study design and treatments
Study design is shown in Figure 1. The 20-week RCT
12
consisted of a 2-week placebo run-in period one week after
screening, then randomization to a 4-week dose-escalation
period, and a 16-week constant-dose period. We randomly
assigned individuals to once-daily liraglutide 1.2, 1.8, 2.4 or
3.0mg (n¼95, 90, 93 and 93) or placebo (n¼98) by evening
subcutaneous injection, starting at 0.6mg per day and
increasing weekly (dose escalation). The open-label com-
parator group (n¼95) was randomized to receive orlistat
capsules (3 120mg) with each main meal for the full 2-year
period. After 20 weeks, participants could consent to enroll
in the extension, continuing on randomized treatment for
1 year, after which liraglutide or placebo-treated individuals
switched to liraglutide 2.4mg, considered the most favorable
dose based on 20-week data analysis. However, when 1-year
results became available, the 3.0mg dose was deemed more
favorable and participants switched to this dose between
weeks 70–96, as sites obtained ethics committee approval.
In the main 20-week trial, eligible participants, sponsor
and all study personnel were blinded to the random
injection treatment assignment, performed using a sponsor-
generated central telephone or web-based system, generated
by the sponsor and concealed from trial investigators. A
balanced (1:1) treatment allocation was specified, stratified
by gender. We instructed participants receiving liraglutide or
placebo to administer daily injections (liraglutide
6.0mgml
 1 or vehicle in identical 3ml cartridges) in the
abdomen or thigh each evening, using a pen injector. Four
different placebo injection volumes corresponded to the
different liraglutide doses, thereby masking treatment
(active/placebo).
From 20 to 52 weeks, participants/investigators remained
blinded to liraglutide/placebo treatment but the sponsor/
statistician was unblinded; after 1 year, all were unblinded.
Throughout run-in and treatment, participants were advised
on diet (about 30% of energy from fat, 20% from protein and
50% from carbohydrates), providing an energy deficit of
B500kcal per day, and encouraged to maintain or increase
physical activity. To encourage adherence, pedometers were
distributed, and a 3-day food diary was dispensed for
completion 4 times during the trial, and reviewed by a
dietician.
The trial ran from January 2007 to April 2009 and is
registered with Clinicaltrials.gov, number NCT00480909.
Clinical outcomes
Efficacy endpoints included weight change from randomiza-
tion to years 1 and 2 in the intention-to-treat population, the
proportion losing 45o r410% of randomization weight,
and changes in waist circumference, BP, prevalence of
prediabetes
14 and metabolic syndrome,
15,16 glycemic para-
meters, fasting lipids and cardiovascular biomarkers, and
quality of life.
17 Prediabetes was defined
14 as either impaired
FPG (5.6–6.9mmoll
 1) or impaired glucose tolerance
(7.8–11.0mmoll
 1) after 2-hour oral glucose tolerance test
(75g glucose). The diagnosis of metabolic syndrome was
made according to updated National Cholesterol Education
Program-Adult Treatment Panel III (NCEP-ATP III) criter-
ia.
15,16 Body composition in a subgroup of participants was
measured at randomization and week 20 only by dual-energy
X-ray absorptiometry and single-slice abdominal computer-
ized axial tomography. Fully blinded specialists at SYNARC
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Paris, France (computerized axial tomography) analyzed the
scans. We measured weight and BP from screening, so effects
on total weight-loss maintenance could be determined post
hoc. All other efficacy parameters were measured from
randomization, so that effects of liraglutide treatment versus
placebo and orlistat could be assessed.
7
Safety assessments included adverse events, recorded at
every visit, standard laboratory tests and serum liraglutide
antibodies. Antibody-positive samples were further assessed
for neutralizing effect (against liraglutide) and crossreactivity
(to GLP-1) in vitro. We measured serum calcitonin as thyroid
C-cell tumors have been detected in liraglutide-treated
rodents.
18 MDS Pharma Services (Hamburg, Germany)
performed the standard laboratory analyses, and Ligand
Binding Services, MDS Pharma Services (Fehraltorf, Switzerland)
analyzed the liraglutide antibody concentration. A safety
committee for data surveillance was established.
Clinic visits over the 2-year trial period were weekly during
dose escalation, otherwise, every 4 weeks. Weight was
measured at every visit from screening. Standardized waist
circumference assessments were made at randomization,
then every 4 weeks. BP, glycemic parameters and lipids were
measured at randomization, every 4 weeks to week 24, then
at weeks 32, 44, 52, 64, 76, 88, 100 and 104; BP was also
measured at screening. Metabolic syndrome status, predia-
betes status, cardiovascular biomarkers and glycated hemo-
globin (HbA1c) and quality of life were assessed at
randomization, week 20, week 52 and week 104. Participants
underwent physical examination and electrocardiogram at
screening, week 20, week 52 and week 104. Pulse rate and
laboratory parameters were measured at screening, run-in
(laboratory parameters only), randomization, every 4 weeks
to week 24, then at weeks 32, 44, 52 and 104. Calcitonin
concentration was categorized by one of four categories:
olower level of quantification (LLOQ); XLLOQ and oupper
normal range (UNR); XUNR and o2 UNR; and X2 UNR.
Statistical analysis
Sample size estimation for the 20-week trial was based on
the primary outcome weight. It was assumed that the s.d. for
weight change at week 20 would be 5.6kg;
19 547 randomized
individuals (91 per group) provided X85% confidence to
detect a clinically relevant 3kg difference (P¼0.05, two-
sided) in mean weight between people dosed with liraglutide
and placebo, based on Dunnett’s test.
20 A drop-out rate
of 30% after 20 weeks was assumed. The objective of
the extension was to evaluate safety and weight-loss
durability. Data were analyzed according to a pre-established
analysis plan. All analyses were performed on a modified
intention-to-treat population, comprising all randomized
individuals who received at least one treatment dose and had
at least one post-randomization assessment of body weight,
with the last-observation-carried-forward for efficacy end-
points (unless stated).
7 Analysis of completers (those in the
intention-to-treat population who completed the trial
period) from screening was also performed post hoc. All
analyses were two-sided, with 5% significance. The numbers
of values that were imputed at year 1 and year 2 for the
parameters weight, waist circumference, BP, fasting lipids,
prediabetes and metabolic syndrome are shown in Supple-
mentary Table 1.
We analyzed 1-year weight, waist, BP and 20-week body
composition (also glycemic parameters, fasting lipids, cardi-
ovascular biomarkers and pulse post hoc) by analysis of
covariance (ANCOVA), investigating the superiority of each
of the four doses of liraglutide over placebo (primary
objective) and orlistat (secondary objective). At year 2, the
superiority of liraglutide (in a pooled group of participants
who were on 2.4/3.0mg for 2 years) versus orlistat was
assessed. Treatment, country and sex were fixed effects; the
value of the respective parameter at randomization was a
covariate. The primary null hypothesis was that there was no
difference between treatments. We adjusted for multiplicity
using Dunnett’s method.
20
Liraglutide 2.4 mg
Liraglutide 3.0 mg s.c.
Randomization
n=564 
Screening:
Wk -3
Placebo
run-in:
Wk -2
20 weeks
472 completed
    year 2 
 268 completed
year 1
356 completed
Placebo s.c.
Orlistat 120 mg x3
Liraglutide 1.8 mg s.c.
Liraglutide 2.4 mg s.c.
Liraglutide 1.2 mg s.c.
Lifestyle intervention: -500 kcal/day deficit diet + increased physical activity
Extension*
n=398
Double blind
BMI ≥30 and ≤40 kg/m2
Age 18–65 years
Stable body weight
FPG <7.0 mmol/L at Wk -2
Inclusion criteria:
Liraglutide 3.0 mg
Switch was 
when approved locally
 (between 70–96 weeks)
Figure 1 Study design. *From 20–52 weeks, participants/investigators remained blinded to liraglutide/placebo treatment but the sponsor was unblinded; after
1 year, all were unblinded.
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repeated measures analyses were performed using the long-
itudinal measurements available for the modified intention-to-
treat population. These analyses were planned at year 1 and
were performed post hoc at year 2. The repeated measures model
included the same effects as the ANCOVA model described
above. Interactions between treatment and visit, country and
visit, and sex and visit were also included, with the restriction
that, for visits in the dose-escalation period (weeks 1–4), means
for treatment groups having received the same treatment up to
the given visit were assumed to be equal. Evaluations of
superiority of each liraglutide dose to placebo (primary
objective) and to orlistat (secondary objective) were carried
out using the Bonferroni adjustment for multiple testing.
The proportions of individuals losing 45 and 410%
weight were analyzed by logistic regression, using the same
model parameters (without country), with multiplicity
adjustment using Bonferroni correction. As ‘country’showed
no significant effect it was removed from the model, to allow
inclusion of a greater number of variables and to increase the
accuracy of the estimates. Prediabetes and calcitonin were
also analyzed by logistic regression, as were metabolic
syndrome status and nausea/vomiting incidence post hoc.
The logistic regression analysis for calcitonin noted if a trial
participant moved up one category from randomization to
year 2. Randomization means for treatment groups in all the
above analyses were assumed to be equal. We used the
Statistical Analysis System software package (version 9.1; SAS
Institute, Cary, NC, USA) for all analyses.
Results
Trial population
Of 616 individuals entering the 2-week run-in, 135 men and
429 women (n¼564) were randomized to treatment, 398
entered the extension and 268/398 (67%) completed 2 years
(see Supplementary Figure 1). Included in the trial were
21 individuals (o4% overall) classified as having a rando-
mization glucose concentration in the range of type 2
diabetes mellitus; this had developed since screening. Three
liraglutide-treated participants were excluded from the
intention-to-treat population owing to missing post-rando-
mization weight data. Major protocol deviations are
described in the Supplementary Information.
Participant characteristics were comparable across groups
at randomization (Supplementary Table 2)
12 and entering
the extension (not shown).
Weight and waist circumference from randomization
For the intention-to-treat population (with last-observation-
carried-forward), estimated mean weight loss from randomi-
zation to year 1 was significantly greater with liraglutide
1.8–3.0mg compared with placebo, and was dose-dependent
(Figure 2a, ANCOVA). Placebo-subtracted mean weight loss
was 5.8kg (95% confidence interval 3.7–8.0) with liraglutide
3.0mg. Mean change in waist circumference was signifi-
cantly greater with liraglutide 2.4–3.0mg versus placebo.
Weight loss for those on liraglutide 2.4/3.0mg for 2 years was
significantly greater than with orlistat. No gender differences
in weight loss were observed (data not shown). Body
composition results in subgroup participants showed that
20-week weight loss with liraglutide was primarily from fat
tissue (Table 1).
Significantly more individuals on liraglutide 1.8–3.0mg
achieved weight losses 45 and 410% of randomization
weight versus placebo at year 1 (Figure 2b). At year 2,
significantly more on liraglutide 2.4/3.0mg than on orlistat
lost 45 and 410% weight. Of the 64% who achieved 45%
weight loss with liraglutide 2.4/3.0mg at year 1, 485%
maintained this at year 2.
Blood pressure and pulse from randomization
Mean systolic and diastolic BP decreased in all groups over 1
year, and systolic BP remained significantly lower with
liraglutide 2.4/3.0mg than orlistat at 2 years, while pulse
rate was 3.5beatsmin
 1 greater (Figure 2c).
Maintenance from screening: weight loss, BP reduction and pulse
Mean weight reduction between screening and randomiza-
tion was 1.3±1.4kg across groups. Figure 3a shows that
participants randomized to liraglutide 3.0mg for 1 year (and
then maintained on 2.4/3.0mg for the second year) main-
tained a mean weight loss of 10.3±7.1kg from screening
over 2 years. Weight loss for the pooled group on liraglutide
2.4/3.0mg for 2 years was estimated to be 7.8kg by adjusted
ANCOVA (Supplementary Figure 2a). Almost 70% of liraglu-
tide 2.4/3.0mg recipients maintained weight loss 45% of
screening weight at year 2, 43% maintained 410% loss and
25% maintained 415% loss (Supplementary Figure 2b).
Between screening and randomization, across all groups,
mean systolic BP decreased by 5.7±11.0mmHg, diastolic BP
by 3.7±8.1mmHg and pulse rate fell by 0.9±10.1
beatsmin
 1. For completers on liraglutide 2.4/3.0mg, mean
systolic BP had decreased from screening levels by
12.5mmHg at year 2 (Figure 3b). With liraglutide, mean
pulse rate rose slightly from randomization in the first 30
weeks of the trial (Figure 3c), but subsequently fell,
approximately to screening levels (Figures 3b and c).
Repeated measures analyses of weight, waist and BP
At years 1 and 2, the repeated measures analyses, performed
in support of the primary ANCOVA analyses, in general gave
slightly greater estimates for weight and waist change,
slightly lower estimates for systolic BP and similar estimates
for diastolic BP (Supplementary Tables 3 and 4). In terms of
superiority, results of the repeated measures analyses were in
general comparable to those of the ANCOVA analyses.
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Over the 2-year period, 222 (39%) individuals withdrew from
the trial: 34–43% of those randomized to liraglutide, and
40% of those randomized to placebo or orlistat. Adverse
events include data previously reported for the 20-week
trial.
12 Summary data for year 1 are shown in Table 2, and in
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Figure 2 (a) Mean changes in body weight and waist circumference from randomization to years 1 and 2. (b) Participants with 45 and 410%
randomization weight loss at years 1 and 2. (c) Mean changes in BP and pulse rate from randomization to years 1 and 2. Estimated mean changes in weight,
waist, BP and pulse rate (by ANCOVA), and in weight-loss responders (by logistic regression) are shown for the intention-to-treat population with the last observation
carried forward.
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liraglutide-associated side effects were gastrointestinal
(Table 2; Supplementary Table 6). In year 1, more partici-
pants reported nausea and/or vomiting with liraglutide
3.0mg (49/93; 53%) than with lower doses, placebo (8/98;
8%) (Po0.0001) or orlistat (7/95; 7%)(Po0.0001). Most
nausea/vomiting episodes started in weeks 1–6, were tran-
sient and 490% were of mild or moderate intensity. Few
episodes were serious (2 vomiting). Nausea incidence over 2
years was similar for males and females (P¼0.49).
Mean 1-year weight loss from randomization with liraglu-
tide 3.0mg was 10.0kg for those with nausea and/or
vomiting (n¼49) and 7.1kg for those without
(n¼43)(difference 2.9kg (95% confidence interval 0.5–5.3);
P¼0.02). Weight loss without nausea and/or vomiting was
still 4.2kg greater than placebo (P¼0.0001) and 2.3kg
greater than orlistat (P¼0.04).
No participant discontinued treatment owing to aversion
to injections or injection-site disorders during run-in
(Supplementary Figure 1). A total of 51 individuals (9%)
withdrew from the trial over 2 years owing to adverse events.
These were mostly gastrointestinal. Over 2 years, 15/371
(4%) liraglutide-treated individuals discontinued owing to
nausea and/or vomiting; none on placebo (in year 1) or
orlistat did so. Four on liraglutide 2.4mg discontinued
because of injection-site disorders (pain/extravasation;
hematoma; irritation; and discomfort). Four individuals, all
female and randomized to liraglutide treatment, were with-
drawn owing to serious adverse events. One withdrew owing
to a serious event of cholelithiasis, occurring simultaneously
with acute pancreatitis, after 299 days on liraglutide 3.0mg;
the individual recovered without sequelae. Breast cancer
occurred in an individual randomized to liraglutide 1.8mg
and treated with 2.4mg at the time of the event, which was
reported after 465 days of treatment. The individual subse-
quently withdrew from the trial. A serious intestinal adeno-
carcinoma was reported by a female participant after 410 days
on liraglutide 2.4mg, after a screening program for lung
cancer during the trial revealed metastases in the liver. The
individual withdrew from the trial and was not expected to
recover. A serious anaphylactic reaction was reported by one
individual after 692 days of treatment with liraglutide 3.0mg.
The event was due, according to the hospital to which the
individual was admitted, to administration of diclofenac/
misoprostol on the day of the reaction. The individual
recovered but later withdrew from the trial. A further three
serious adverse events of special interest and in the liraglutide
group were events of atrial fibrillation, uterine leiomyoma
and prostate cancer. A serious cardiovascular episode (atrial
fibrillation) was reported in a male individual randomized to
placebo but on liraglutide 3.0mg at the time of the event,
which occurred after 707 days. Treatment was temporarily
discontinued; the participant recovered and completed the
trial without further events. The uterine leiomyoma occurred
Table 1 Body composition assessed by dual-energy X-ray absorptiometry and computerized axial tomography in a subgroup of participants at 20 weeks
Placebo
n¼14
Liraglutide Orlistat
n¼12
1.2mg
n¼15
1.8mg
n¼13
2.4mg
n¼15
3.0mg
n¼15
Dual-energy X-ray absorptiometry measurements: body composition at randomization (kg)
a
Fat tissue 45.8 (10.5) 43.5 (7.6) 45.0 (8.8) 42.6 (6.1) 43.9 (8.4) 41.3 (6.7)
Lean tissue 51.0 (11.0) 55.0 (8.9) 51.7 (11.3) 50.6 (11.9) 53.1 (10.3) 47.4 (6.4)
Relative change at week 20 (%)
Fat tissue
b  11.9 (2.5)  13.9 (2.7)  13.0 (2.6)  16.5 (2.5)  15.4 (2.6)  13.3 (2.9)
Change vs placebo
c F  2.0 ( 8.9 to 4.9);
P¼0.57
 1.1 ( 8.0 to 5.9);
P¼0.76
 4.6 ( 11.2 to 2.1);
P¼0.18
 3.5 ( 10.3 to 3.4);
P¼0.32
F
Lean tissue
b  1.3 (1.0)  0.9 (1.1)  2.9 (1.1)  2.6 (1.0)  2.0 (1.1) 0.9 (1.2)
Change vs placebo
c F 0.4 ( 2.4 to 3.3);
P¼0.77
 1.6 ( 4.4 to 1.3);
P¼0.28
 1.3 ( 4.1 to 1.4);
P¼0.33
 0.7 ( 3.6 to 2.1);
P¼0.61
F
Computerized axial tomography measurements: body composition at randomization (cm
2)
a
Visceral fat 136 (38) 172 (77) 121 (39) 149 (76) 145 (69) 101 (40)
Subcutaneous fat 474 (107) 453 (68) 476 (71) 426 (75) 434 (116) 459 (113)
Relative change at week 20 (%)
Visceral fat
b  13.8 (5.7)  19.0 (6.3)  19.4 (6.0)  23.0 (5.7)  20.3 (6.0)  20.2 (6.7)
Change vs placebo
c F  5.1 ( 21.2 to 11.0);
P¼0.53
 5.6 ( 21.8 to 10.6);
P¼0.49
 9.2 ( 24.7 to 6.4);
P¼0.25
 6.4 ( 22.1 to 9.2);
P¼0.42
F
Subcutaneous fat
b  12.1 (3.0)  15.6 (3.3)  15.9 (3.6)  19.3 (3.0)  15.3 (3.3)  17.9 (3.6)
Change vs placebo
c F  3.5 ( 11.8 to 4.9);
P¼0.41
 3.8 ( 12.6 to 5.1);
P¼0.40
 7.1 ( 15.2 to 1.0);
P¼0.09
 3.1 ( 11.5 to 5.2);
P¼0.45
F
aMean (s.d.).
bEstimated mean (s.e.).
cEstimated mean (95% CI); P-value. Values are for participants who completed the substudy according to the protocol
(PP completers).
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International Journal of Obesityin a participant on 2.4mg liraglutide for 219 days, who was
diagnosed with single fungal fibroid, underwent hysterec-
tomy, but later recovered. Prostate cancer was detected in an
individual on liraglutide 1.8mg after 94 days of treatment.
Trial drug continued unchanged throughout the event, the
individual completed the trial and was reported as recovering.
A psychiatric medical history was present in 96/564 (17%)
participants. In year 1, the most frequently reported disorder
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Figure 3 (a) Change in body weight from screening over 2 years, presented as observed data for individuals completing each scheduled visit. (b) Estimated
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data for the intention-to-treat population (with no imputation).
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International Journal of Obesitycoded as ‘psychiatric’ was insomnia (Table 2). Other
frequently reported disorders included stress, depression,
depressed mood and anxiety. All were non-serious and of
mild or moderate severity. Overall, there were more
psychiatric disorders in general reported by participants on
2.4 and 3.0mg liraglutide than those on placebo, but there
did not seem to be any pattern to the disorders reported,
with specific events (other than insomnia) being reported by
p3 participants in any group. Two participants withdrew
because of anxiety (placebo) and food aversion (liraglutide
1.2mg).
Over 2 years, 13 self-reported events of symptomatic
hypoglycemia (unconfirmed by blood glucose measurement,
non-serious) were reported by 9 individuals: 1 event in
placebo and 12 in liraglutide-treated participants. No
changes in calcitonin concentration were noted at 2 years.
Most calcitonin assessments were below the upper normal
limit during the 2-year trial period, and no differences in
mean concentrations were observed between liraglutide
2.4/3.0mg and orlistat by logistic regression (estimated odds
ratio for liraglutide 2.4/3.0mg versus orlistat was 0.5 (95%
confidence interval 0.17–1.6); P¼0.26).
Seven individuals developed antibodies to liraglutide over
the 2-year trial period (6 on liraglutide and 1 on orlistat).
One subject randomized to liraglutide 1.2mg had antibodies
that crossreacted to GLP-1 in vitro at the end of the trial
(the subject was exposed to both liraglutide 2.4 and 3.0mg
during the extension period).
Quality of life improved in all groups at year 1 (Supple-
mentary Table 7) and year 2 (not shown).
Other secondary endpoints from randomization
At randomization, 176/564 (31%) individuals had predia-
betes, and 229/564 (41%) met criteria for metabolic
syndrome. Prediabetes prevalence was significantly reduced
with liraglutide 1.8–3.0mg versus both placebo and orlistat
at year 1, and with liraglutide 2.4/3.0mg versus orlistat at
Table 2 Summary of safety data, gastrointestinal disorders with an incidence of X5% in any group and all psychiatric disorders in year 1
Placebo n¼98 Liraglutide Orlistat n¼95
1.2mg n¼95 1.8mg n¼90 2.4mg n¼93 3.0mg n¼93
N (%) E N (%) E N (%) E N (%) E N (%) E N (%) E
Summary of safety data
Overall withdrawal rate
a 24 (25) 17 (18) 20 (22) 27 (29) 18 (19) 28 (30)
Participants with AEs 87 (88.8) 374 88 (92.6) 362 84 (93.3) 430 88 (94.6) 485 89 (95.7) 492 89 (93.7) 372
Participants with any SAE 3 (3.1) 3 2 (2.1) 2 7 (7.8) 7 4 (4.3) 5 7 (7.5) 10 2 (2.1) 2
Withdrawals due to AEs 3 (3.1) 7 5 (5.3) 12 6 (6.7) 10 12 (12.9) 20 7 (7.5) 12 3 (3.2) 3
Gastrointestinal disorders 37 (37.8) 62 55 (57.9) 101 58 (64.4) 121 66 (71.0) 157 72 (77.4) 167 60 (63.2) 110
Abdominal pain 4 (4.1) 4 2 (2.1) 2 3 (3.3) 3 1 (1.1) 1 5 (5.4) 5 4 (4.2) 5
Abdominal pain upper 1 (1.0) 1 5 (5.3) 6 2 (2.2) 3 5 (5.4) 5 5 (5.4) 7 7 (7.4) 8
Constipation 12 (12.2) 14 15 (15.8) 17 11 (12.2) 12 21 (22.6) 24 17 (18.3) 18 7 (7.4) 8
Diarrhea 10 (10.2) 11 8 (8.4) 13 9 (10.0) 12 12 (12.9) 13 14 (15.1) 15 28 (29.5) 40
Dyspepsia 3 (3.1) 3 6 (6.3) 7 7 (7.8) 7 9 (9.7) 13 8 (8.6) 8 3 (3.2) 4
Flatulence 1 (1.0) 1 F 4 (4.4) 4 4 (4.3) 4 3 (3.2) 3 10 (10.5) 10
Nausea 7 (7.1) 8 23 (24.2) 27 29 (32.2) 33 35 (37.6) 48 45 (48.4) 68 7 (7.4) 7
Steatorrhea FFFFF 5 (5.3) 5
Toothache 1 (1.0) 1 1 (1.1) 1 5 (5.6) 7 1 (1.1) 1 F 1 (1.1) 1
Vomiting 2 (2.0) 2 5 (5.3) 6 9 (10.0) 18 14 (15.1) 17 12 (12.9) 16 2 (2.1) 4
Psychiatric disorders 5 (5.1) 5 3 (3.2) 3 4 (4.4) 4 11 (11.8) 14 12 (12.9) 14 5 (5.3) 8
Acute stress disorder FFF 1 (1.1) 1 FF
Affect lability FFFFF 1 (1.1) 1
Alcohol abuse FFFFF 1 (1.1) 1
Anxiety 1 (1.0) 1 FF 2 (2.2) 2 2 (2.2) 2 F
Burnout syndrome FFFF 1 (1.1) 1 F
Depressed mood F 1 (1.1) 1 F 3 (3.2) 3 1 (1.1) 1 F
Depression FF 2 (2.2) 2 2 (2.2) 2 1 (1.1) 1 2 (2.1) 3
Eating disorder FFF 1 (1.1) 1 FF
Food aversion F 1 (1.1) 1 FFFF
Insomnia 2 (2.0) 2 FF 2 (2.2) 2 5 (5.4) 6 2 (2.1) 3
Mood altered FFF 1 (1.1) 1 1 (1.1) 1 F
Nervousness FFF 2 (2.2) 2 FF
Restlessness FF 1 (1.1) 1 FFF
Stress 2 (2.0) 2 1 (1.1) 1 1 (1.1) 1 F 2 (2.2) 2 F
Abbreviations: AE, adverse event; E, number of adverse event; N (%), number and proportion of participants with an adverse event; SAE, serious adverse event.
aDoes
not include individuals who chose not to enroll in the extension period.
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International Journal of Obesityyear 2 (Figure 4a). Between 52–62% of liraglutide-treated
individuals with prediabetes at randomization achieved
normal glucose tolerance at year 2, compared with 26% of
those on orlistat. At year 1, the prevalence of metabolic
syndrome decreased significantly with liraglutide 1.8–3.0mg
compared with placebo, and was reduced with both liraglu-
tide 2.4/3.0mg and orlistat at year 2.
Fasting lipids, glycemic parameters and cardiovascular
risk factors were first measured at randomization, so
changes associated with weight loss between screening
and randomization are not accounted for. No effects of
liraglutide versus placebo on fasting lipids were apparent
after 1 year (Figure 4b). At year 2, high-density lipoprotein
cholesterol significantly increased with liraglutide 2.4/
3.0mg versus orlistat (treatment difference 0.07mmoll
 1,
P¼0.03), and both low-density lipoprotein cholesterol
and triglycerides decreased from randomization with liraglu-
tide 2.4/3.0mg (treatment difference  0.12mmoll
 1 for
triglycerides, P¼0.053 versus orlistat). Mean FPG and
glycated hemoglobin (HbA1c) decreased significantly with
all liraglutide doses versus placebo at year 1 and with
liraglutide 2.4/3.0mg versus orlistat at year 2 (Supplemen-
tary Figure 3).
Plasminogen activator inhibitor-1 significantly decreased
with liraglutide 3.0mg versus placebo (Supplementary
Table 8); otherwise, no significant liraglutide effects
on cardiovascular biomarkers were observed at year 1.
Fibrinogen concentrations decreased across groups, while
adiponectin levels increased.
Discussion
Over 2 years, liraglutide with a diet and exercise program was
well tolerated, produced sustained weight loss and reduced
important cardiovascular risk factors in obese non-diabetic
adults. Estimated weight loss of 7.8kg and systolic BP
decrease of 12.5mmHg was sustained with liraglutide
2.4/3.0mg in completers from screening. In obesity trials,
the intervention includes weight loss achieved during run-
in, before drug exposure, during which lifestyle changes are
initiated, and, from a patient perspective, represents the
total effect on weight loss. Furthermore, biochemical and
other parameters change during this weight-loss period: for
example, the initial weight loss of 1.3kg seen in the current
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Figure 4 (a) The prevalence of prediabetes and the metabolic syndrome at randomization and after 1 and 2 years of treatment. Metabolic syndrome is defined by
updated NCEP-ATP III criteria.
16 (b) Mean changes in lipids from randomization to years 1 and 2. Estimated (ANCOVA) changes are shown for the intention-to-treat
population with the last observation carried forward.
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International Journal of Obesitytrial was associated with an immediate reduction in systolic
BP of 5.7mmHg (in completers), so where screening data
exist we have additionally reported these. From randomiza-
tion, reductions in FPG, HbA1c, and in the prevalence of
prediabetes and metabolic syndrome, were observed during
the trial.
At year 1, superior weight loss with liraglutide (7.8kg) over
both placebo (2.0kg) and orlistat (3.9kg) was demonstrated.
Mean placebo-subtracted weight loss of 5.8kg from rando-
mization with liraglutide 3.0mg was 1.5kg more than with
sibutramine in similar 1-year trials.
21 Weight loss stabilized
by about 36 weeks, similar to trials with other weight-loss
agents,
22,23 was maintained over 2 years and was signifi-
cantly greater with liraglutide 2.4/3.0mg than with orlistat.
Importantly, almost 70% of participants on liraglutide
2.4/3.0mg over 2 years maintained a 45% weight loss from
screening, associated with improvements in several cardio-
vascular risk factors and metabolic abnormalities.
4,5
Liraglutide-associated weight loss, in this population not
selected for hypertension, was accompanied by decreased
systolic BP and unchanged pulse rate at 2 years from
screening. Compared with orlistat, BP was lower and pulse
rate higher. The clinical significance of the initial pulse
increase with liraglutide, as has been reported previously,
10
in the context of decreased systolic BP, remains unknown.
At year 2, the prevalence of prediabetes was reduced with
liraglutide 2.4/3.0mg by over 50%. Mean FPG and HbA1c
concentrations were also reduced, as in previous studies with
liraglutide in type 2 diabetes.
10,11 A significant increase in
high-density lipoprotein cholesterol, and marked (nonsig-
nificant) decrease in triglycerides, was noted with liraglutide
2.4/3.0mg versus orlistat. Changes in low-density lipopro-
tein cholesterol were comparable to those observed with
orlistat, whose mode of action includes reduced dietary fat
absorption.
Obesity is associated with altered expression of adipocy-
tokines and risk factors for cardiovascular disease.
24,25 In
agreement with previous studies,
25 weight loss in all groups
increased concentrations of adiponectin and reduced fibri-
nogen levels.
26 Concentrations of plasminogen activator
inhibitor-1, which inhibits endogenous fibrinolysis, are
reduced by diet and exercise,
25 as observed here for all
groups except orlistat; liraglutide 3.0mg produced signifi-
cantly greater reduction than diet and exercise alone at
year 1. These data concur with effects demonstrated with
liraglutide in patients with type 2 diabetes.
27 Reductions in
highly sensitive C-reactive protein were also observed with
liraglutide and orlistat, as noted previously.
25 In the light of
the current focus on cardiovascular safety of weight-loss
drugs,
28,29 the favorable effect on cardiovascular risk factors
in the current trial seems promising.
Liraglutide was generally well tolerated and improved
quality of life. Adverse events were mostly mild or moderate.
Gastrointestinal events (particularly nausea and vomiting),
consistent with the known physiological effects of GLP-1,
were more frequent than with placebo. At year 1, nausea
and/or vomiting was associated with greater weight loss with
liraglutide 3.0mg, but even those who did not experience
these events lost more weight than those on placebo or
orlistat. The injection regimen did not impair adherence or
cause significant withdrawal during treatment or run-in.
The main study limitations are the complex study design
and the open-label nature of the orlistat treatment arm,
although this represents existing best pharmacological
practice and provides a comparison for the long-term safety
data of liraglutide over the 2-year period. The lack of the
placebo comparison at 2 years is also a limitation, but it did
not seem feasible in terms of participant retention to
maintain the placebo arm. The presence of a diet and
exercise run-in period in the study design complicates
analyses, and limits the capacity of the trial to anticipate
the total maintained effects of treatment. Most secondary
endpoints were not measured at screening, therefore several
biochemical changes brought about by weight loss during
run-in cannot be evaluated. Lipids are likely to have
improved; a 6% decrease in low-density lipoprotein and
total cholesterol concentrations was previously observed
during 2-week run-in in a trial of orlistat versus placebo
treatment.
30 Analyses from randomization should be inter-
preted in this light. The initial choice of 2.4mg as a long-
term maintenance dose after 1 year was based on 20-week
data. However, when the 12-month data were analyzed, and
the decision taken to move up to 3.0mg, the non-uniform
time for dose-switch from liraglutide 2.4 to 3.0mg during
year 2 (as a result of differences in local ethical committee
efficiency) is also a limitation. No participants had the
benefit of the 3.0mg dose for the full 2 years, and some for as
little as 8 weeks.
In conclusion, results of this study indicate the ability of
liraglutide, with diet and exercise, to provide sustained
weight loss over 2 years, greater efficacy compared to orlistat
and improvements in many of the important obesity-
associated metabolic and cardiovascular risk factors. There
were no major safety issues, confirming data from the LEAD
trials in people with type 2 diabetes at liraglutide doses up to
1.8mg.
10,11 However, it will be necessary to confirm these
results in a larger phase 3 program in obese adults, both in
terms of efficacy and (particularly) safety and tolerability.
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